Literature DB >> 8675965

Sertraline 50 mg daily: the optimal dose in the treatment of depression.

S H Preskorn1, R M Lane.   

Abstract

The dose regimen for sertraline in the treatment of depression has been well established. The starting dose, 50 mg/day, is the usually effective therapeutic dose, and the optimal dose when considering both efficacy and tolerability for most patients. For patients who do not show an adequate therapeutic response within 24 weeks, the dose of sertraline can be increased in 50 mg/day increments at no less than weekly intervals to a maximum of 200 mg/day. Sertraline is generally given as a single daily dose and may be administered at any time of the day. In contrast to other selective serotonin reuptake inhibitors, there is no need for altered dose recommendations in the elderly.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8675965     DOI: 10.1097/00004850-199510030-00001

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  12 in total

1.  Sertraline delays relapse in recently abstinent cocaine-dependent patients with depressive symptoms.

Authors:  Alison Oliveto; James Poling; Michael J Mancino; D Keith Williams; Jeff Thostenson; Rhonda Pruzinsky; Kishorchandra Gonsai; Mehmet Sofuoglu; Gerardo Gonzalez; Shanti Tripathi; Thomas R Kosten
Journal:  Addiction       Date:  2011-10-10       Impact factor: 6.526

Review 2.  Sertraline. A pharmacoeconomic evaluation of its use in depression.

Authors:  R Davis; M I Wilde
Journal:  Pharmacoeconomics       Date:  1996-10       Impact factor: 4.981

3.  Effect of sertraline on protein binding of warfarin.

Authors:  G Apseloff; K D Wilner; N Gerber; L M Tremaine
Journal:  Clin Pharmacokinet       Date:  1997       Impact factor: 6.447

4.  A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide.

Authors:  L M Tremaine; K D Wilner; S H Preskorn
Journal:  Clin Pharmacokinet       Date:  1997       Impact factor: 6.447

Review 5.  The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders.

Authors:  G MacQueen; L Born; M Steiner
Journal:  CNS Drug Rev       Date:  2001

6.  The influence of 4-week treatment with sertraline on the combined T3/TRH test in depressed patients.

Authors:  Cornelius Schüle; Thomas C Baghai; Lejla Alajbegovic; Markus Schwarz; Peter Zwanzger; Daniela Eser; Ludwig Schaaf; Hans-Jürgen Möller; Rainer Rupprecht
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-03-05       Impact factor: 5.270

Review 7.  Clinical pharmacokinetics of darunavir.

Authors:  Michael Rittweger; Keikawus Arastéh
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

8.  Clinical efficacy of sertraline alone and augmented with gabapentin in recently abstinent cocaine-dependent patients with depressive symptoms.

Authors:  Michael J Mancino; Janette McGaugh; Mohit P Chopra; Joseph B Guise; Christopher Cargile; D Keith Williams; Jeff Thostenson; Thomas R Kosten; Nichole Sanders; Alison Oliveto
Journal:  J Clin Psychopharmacol       Date:  2014-04       Impact factor: 3.153

Review 9.  The effect of increased serotonergic neurotransmission on aggression: a critical meta-analytical review of preclinical studies.

Authors:  Maria Carrillo; Lesley A Ricci; Glen A Coppersmith; Richard H Melloni
Journal:  Psychopharmacology (Berl)       Date:  2009-04-30       Impact factor: 4.530

10.  Selective serotonin reuptake inhibitor use in primary care: a 5-year naturalistic study.

Authors:  J Donoghue
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.